Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

New York Slip and Fall Lawyer Steven Louros, Esq. Releases Sidewalk Slip and Fall Resource

April 4, 2026

RAKIA Achieves CMMC Level 1 Compliance, Expanding Access to U.S. Defense Contracts and Accelerating Federal Growth Strategy

April 4, 2026

Patient stabbed in Edmonton ER waiting room as dozens witness attack

April 4, 2026

From ‘bird leg syndrome’ to solar storms: Roberta Bondar breaks down Artemis II mission

April 4, 2026

Why the Iran war has renewed calls for a sovereign medical supply chain

April 4, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Rare Disease Diagnostics Emerging Technologies and Developments Report – Shift Towards a Multi-omics Approach, Collaboration Between Rare Disease Diagnostics and Pharma Companies
Press Release

Rare Disease Diagnostics Emerging Technologies and Developments Report – Shift Towards a Multi-omics Approach, Collaboration Between Rare Disease Diagnostics and Pharma Companies

By News RoomDecember 16, 20244 Mins Read
Rare Disease Diagnostics Emerging Technologies and Developments Report – Shift Towards a Multi-omics Approach, Collaboration Between Rare Disease Diagnostics and Pharma Companies
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Dec. 16, 2024 (GLOBE NEWSWIRE) — The “Rare Disease Diagnostics: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering.

The Rare Disease Diagnostics Market was valued at USD 21.6 Billion in 2024, and is expected to reach USD 34.7 Billion by 2029, rising at a CAGR of 9.9%.

The goal of this report is to provide a comprehensive study of the global market for rare disease diagnostic clinical testing, both in terms of quantitative and qualitative data, to help readers develop business and growth strategies, assess the market landscape, analyze their positions in the current marketplace, and make informed business decisions regarding rare disease diagnostic products and services. The scope of this report includes molecular genetics, cytogenetics and biochemical clinical testing techniques.BCC Research estimated market data for 2023 (the base year) and forecasts values for 2024 through 2029. Segmentation is based on the analysis platform, analysis target, disease class, test purpose, and region.

Industry growth drivers, restraints, trends, and opportunities in the rare disease diagnostic market are discussed in detail. The report also provides information on the rare disease diagnostic market’s competitive landscape and emerging trends. It also discusses significant large-scale research initiatives that impact rare disease diagnostic applications. It is fascinating to discuss global population-scale sequencing projects and their likely impact in linking genetic variation to rare disease diagnostics. The latest news regarding new tests, acquisitions and collaborations related to the rare disease diagnostics market are covered in sufficient detail.

The Report Includes

  • 60 data tables and 70 additional tables
  • An overview of the global market and technologies for rare disease diagnostics
  • Analysis of the global market trends, with data from 2012-2023, estimates for 2024, forecasts for 2025, and projections of compound annual growth rates (CAGRs) through 2029
  • Estimates of actual market size and revenue forecast for the rare disease diagnostics market, and a corresponding market share analysis based on analysis platform, target type, disease category, test purpose, and region
  • A look at the global rare disease diagnostics market structure and technological innovations of the industry
  • Coverage of the factors impacting market growth, trends and opportunities in major regions
  • Discussion about rare disease therapies and how they influence the use of rare disease diagnostics, and details about Orphan Drug Act and other initiatives for rare diseases
  • Information on the key industries associated with developing and marketing rare disease diagnostics, including the DNA sequencing industry, PCR industry, and laboratory services industry
  • A look at the advancements in genomic technologies and analytical tools, and insights into stringent regulatory landscape and ethical and legal concerns
  • Assessment of mergers and acquisitions, joint ventures, partnerships, and other market strategies
  • A discussion of ESG challenges and practices in the industry
  • Company profiles of major players within the industry, including Laboratory Corp. of America Holdings, Quest Diagnostics, Illumina, BGI, and Revvity

Key Attributes:

Report Attribute Details
No. of Pages 131
Forecast Period 2024 – 2029
Estimated Market Value (USD) in 2024 $21.6 Billion
Forecasted Market Value (USD) by 2029 $34.7 Billion
Compound Annual Growth Rate 9.9%
Regions Covered Global

Key Topics Covered:

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary

Chapter 2 Market Overview

  • Rare Diseases Overview
  • Diagnostic Odyssey
  • What Is Genomic Testing?
  • Rare Disease Clinical Assays Development and Marketing
  • Rare Disease Treatment
  • Bioinformatic Resources for Rare Disease Research and Genetic Information
  • Large-Scale Initiatives and Consortia
  • Population Sequencing Programs

Chapter 3 Market Dynamics

  • Market Drivers
    • Significant Unmet Need in Rare Disease Diagnostics
    • Orphan Drug Act
    • Advances In Gene Therapy
    • Rare Disease Initiatives
    • Advances in Genomic Technologies and Analytical Tools
    • Decreasing Cost of Next-Generation Sequencing (NGS)
    • Market Driving Forces and Their Impact on Market Growth
  • Market Restraints
    • Lack of Commercially Available IVDs for Rare Disease Diagnosis
    • Stringent Regulatory Landscape
    • Ethical and Legal Concerns
    • Shortage of Genetic and Rare Disease Specialists

Chapter 4 Emerging Technologies and Developments

  • Shift Towards a Multi-omics Approach
  • Artificial Intelligence (AI) and Machine Learning
  • Collaboration Between Rare Disease Diagnostics and Pharma Companies

Chapter 5 Market Segmentation Analysis

  • Market Breakdown, by Analysis Platform
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • Sanger Sequencing
    • Microarrays
    • Karyotyping and Fluorescent in Situ Hybridization (FISH)
    • Biochemical Testing
  • Market Breakdown, by Analysis Target Type
    • Single Genes
    • Multiple Genes
    • Whole Exome
    • Whole Genome
    • Other Genomic Variants
    • Protein and Other Biochemical Markers
  • Market Breakdown by Disease Class
    • Rare Cancers
    • Neurological Diseases
    • Metabolic and Endocrine Disorders
    • Hematology
    • Respiratory
    • Immune System and Inflammation-Related Disorders
    • Dermatology
    • Musculoskeletal
    • Others
  • Market Breakdown, by Test Purpose
    • Diagnosis
    • Screening and Early Detection
    • Therapy Guidance
    • Monitoring
  • Market Breakdown, by Region

Chapter 6 Competitive Intelligence

  • Strategic Alliances and Developments

Company Profiles

  • 3Billion Inc
  • Ambry Genetics
  • ARUP Laboratories
  • BGI
  • Centogene
  • Dante Omics
  • Illumina
  • Laboratory Corporation of America
  • LetsGetChecked Inc.
  • Quest Diagnostics
  • REVVITY

For more information about this report visit https://www.researchandmarkets.com/r/njgte9

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Rare Disease Diagnostics Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

New York Slip and Fall Lawyer Steven Louros, Esq. Releases Sidewalk Slip and Fall Resource

RAKIA Achieves CMMC Level 1 Compliance, Expanding Access to U.S. Defense Contracts and Accelerating Federal Growth Strategy

Alicia Basir’s April Love Ritual Reconnects Sweethearts for 2026 Wedding

Vapofil Claims Evaluated: 2026 Report on Vapofil Ingredients, Pricing, and What Consumers Should Verify Before Purchasing

HDFC ERGO Shares Tips on Keeping Your No-Claim Bonus Growing for Bigger Long-Term Savings

Free Spins No Deposit Casino Bonus 2026 | Online Casino Real Money No Deposit By My Bookie

Taurox (TAUX) Announced Phase 3 of The Presale Closure After The Last Development Update

Ledruval Unveiled: Is Ledruval Trading Platform Legit? Official Insights, Features & User Feedback

Taurox (TAUX) Announced a Huge Milestone Little After Launch, Receiving Massive Support From Investors

Editors Picks

RAKIA Achieves CMMC Level 1 Compliance, Expanding Access to U.S. Defense Contracts and Accelerating Federal Growth Strategy

April 4, 2026

Patient stabbed in Edmonton ER waiting room as dozens witness attack

April 4, 2026

From ‘bird leg syndrome’ to solar storms: Roberta Bondar breaks down Artemis II mission

April 4, 2026

Why the Iran war has renewed calls for a sovereign medical supply chain

April 4, 2026

Latest News

Iran calls on the public to find the ‘enemy pilot’ as the US continues a frantic search

April 4, 2026

Alicia Basir’s April Love Ritual Reconnects Sweethearts for 2026 Wedding

April 4, 2026

Vapofil Claims Evaluated: 2026 Report on Vapofil Ingredients, Pricing, and What Consumers Should Verify Before Purchasing

April 4, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version